<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613443</url>
  </required_header>
  <id_info>
    <org_study_id>POCT-NOAC</org_study_id>
    <nct_id>NCT01613443</nct_id>
  </id_info>
  <brief_title>Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices</brief_title>
  <official_title>Time-dependent ex Vivo Influence of Rivaroxaban on Point-of-care Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardioangiologisches Centrum Bethanien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardioangiologisches Centrum Bethanien</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concentration determinations of anticoagulants require plasma instead of whole blood, and
      results are not immediately available to clinicians. Monitoring anticoagulants concentration
      along with bedside methods may provide an alternative guide for administration of the NOAC.

      The purpose of this investigation is to compare bedside coagulation assays in whole blood
      with plasma concentrations of the new oral anticoagulants (NOAC) in patients treated with
      therapeutic dosis of NOAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label study will be performed by ex vivo investigations. Patients receiving the
      NOAC as dabigatran or rivaroxaban in therapeutic doses are recruited and informed consent of
      two blood sampling times will be obtained in correlation to the time of drug intake (two and
      24 hours after drug intake). The bedside measurements will be performed and compared directly
      with the concentrations determined by plasma concentration assays. These investigations will
      be performed at the department of Angiology at the university hospital Frankfurt.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Effect of NOAC on POCT</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy volunteers without medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenprocoumon</arm_group_label>
    <description>Patients receiving Marcumar having target INR 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <description>Patients receiving therapeutic dosis of Pradaxa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Patients receiving therapeutic dosis of Xarelto</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients indicated for NOAC-therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The indication for the use of NOAC is provided by the attending physician. The criteria for
        inclusion and exclusion criteria for the use of the new oral anticoagulants must meet
        appropriate eligibility criteria and the clinical guidelines that are described in the
        SOPs.

        Patients treated with dabigatran 2x150mg / d for the prevention of stroke and systemic
        embolism in non-valvular atrial fibrillation are included.

        Moreover, patients treated with rivaroxaban 20 mg / d for DVT prophylaxis and treatment of
        recurrent DVT or PE are included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Mani H, Herth N, Kasper A, Wendt T, Schuettfort G, Weil Y, Pfeilschifter W, Linnemann B, Herrmann E, Lindhoff-Last E. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit. 2014 Oct;36(5):624-31. doi: 10.1097/FTD.0000000000000064.</citation>
    <PMID>24577124</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardioangiologisches Centrum Bethanien</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. E. Lindhoff-Last</investigator_full_name>
    <investigator_title>Prof. Dr. med. Lindhoff-Last</investigator_title>
  </responsible_party>
  <keyword>Dabigatran, Rivaroxaban, Point of Care-testing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

